Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry

医学 经皮冠状动脉介入治疗 阿司匹林 传统PCI 内科学 氯吡格雷 危险系数 人口 心脏病学 急性冠脉综合征 倾向得分匹配 置信区间 心肌梗塞 环境卫生
作者
Chunfeng Dai,Muyin Liu,Zheng Yang,Youran Li,You Zhou,Danbo Lu,Ying Xia,Ao Chen,Chenguang Li,Hao Lu,Yuxiang Dai,Jianying Ma,Zhangwei Chen,Juying Qian,Junbo Ge
出处
期刊:BMC Medicine [BioMed Central]
卷期号:22 (1) 被引量:3
标识
DOI:10.1186/s12916-024-03374-3
摘要

Abstract Background Indobufen is widely used in patients with aspirin intolerance in East Asia. The OPTION trial launched by our cardiac center examined the performance of indobufen based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). However, the vast majority of patients with acute coronary syndrome (ACS) and aspirin intolerance were excluded. We aimed to explore this question in a real-world population. Methods Patients enrolled in the ASPIRATION registry were grouped according to the DAPT strategy that they received after PCI. The primary endpoints were major adverse cardiovascular and cerebrovascular events (MACCE) and Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. Propensity score matching (PSM) was adopted for confounder adjustment. Results A total of 7135 patients were reviewed. After one-year follow-up, the indobufen group was associated with the same risk of MACCE versus the aspirin group after PSM (6.5% vs. 6.5%, hazard ratio [HR] = 0.99, 95% confidence interval [CI] = 0.65 to 1.52, P = 0.978). However, BARC type 2, 3, or 5 bleeding was significantly reduced (3.0% vs. 11.9%, HR = 0.24, 95% CI = 0.15 to 0.40, P < 0.001). These results were generally consistent across different subgroups including aspirin intolerance, except that indobufen appeared to increase the risk of MACCE in patients with ACS. Conclusions Indobufen shared the same risk of MACCE but a lower risk of bleeding after PCI versus aspirin from a real-world perspective. Due to the observational nature of the current analysis, future studies are still warranted to further evaluate the efficacy of indobufen based DAPT, especially in patients with ACS. Trial registration Chinese Clinical Trial Register ( https://www.chictr.org.cn ); Number: ChiCTR2300067274.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zj完成签到,获得积分10
1秒前
蓝橙完成签到,获得积分10
2秒前
6秒前
GD88完成签到,获得积分10
7秒前
糟糕的梨愁完成签到,获得积分10
8秒前
莫西莫西完成签到 ,获得积分10
9秒前
小趴蔡完成签到 ,获得积分10
11秒前
唐唐发布了新的文献求助10
11秒前
飘逸剑身完成签到,获得积分10
14秒前
airtermis完成签到 ,获得积分10
14秒前
gfasdjsjdsjd完成签到,获得积分10
15秒前
15秒前
杨宁完成签到 ,获得积分10
15秒前
MchemG应助transition采纳,获得20
16秒前
科研通AI2S应助科研通管家采纳,获得10
17秒前
lxy发布了新的文献求助10
19秒前
gfasdjsjdsjd发布了新的文献求助10
20秒前
JCao727完成签到,获得积分10
20秒前
20秒前
21秒前
OAHCIL完成签到 ,获得积分10
22秒前
lixueao发布了新的文献求助10
23秒前
无辜的行云完成签到 ,获得积分0
26秒前
FIN应助gfasdjsjdsjd采纳,获得20
28秒前
今后应助gfasdjsjdsjd采纳,获得10
28秒前
排骨炖豆角完成签到 ,获得积分10
30秒前
一叶知秋应助大橙子采纳,获得10
32秒前
kk完成签到,获得积分10
35秒前
敏感春天完成签到,获得积分10
35秒前
凶狠的期待完成签到,获得积分10
37秒前
自然函发布了新的文献求助30
37秒前
JF123_完成签到 ,获得积分10
38秒前
量子星尘发布了新的文献求助10
38秒前
40秒前
杨召发布了新的文献求助10
41秒前
didi完成签到,获得积分10
41秒前
keyby发布了新的文献求助10
43秒前
FashionBoy应助xdc采纳,获得10
48秒前
杨召完成签到,获得积分10
53秒前
大橙子发布了新的文献求助10
57秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022